文献速递青光眼

比较Hydrus与iStent微创青光眼手术植入物单独治疗开角型青光眼的前瞻性随机试验:COMPARE研究

A Prospective Randomized Trial Comparing Hydrus and iStent Microinvasive Glaucoma Surgery Implants for Standalone Treatment of Open-Angle Glaucoma: The COMPARE Study.
PubMed 文献 · Ophthalmology · 2019-04-26

这项前瞻性多中心随机试验将152眼开角型青光眼随机分至Hydrus或2枚iStent单独微创青光眼手术,12个月时Hydrus完全手术成功率更高且用药更少,两组安全性相似。

要点

  • 12个月时Hydrus组完全手术成功率高于2-iStent组(P < 0.001)。
  • Hydrus组用药数较2-iStent组少0.6种(P = 0.004),无用药比例高22.6%(P = 0.0057)。
  • 2-iStent组2眼(3.9%)需再次青光眼手术,Hydrus组无;两组安全性相似。

核心结论

  • Hydrus单独微创青光眼手术治疗开角型青光眼较2枚iStent手术成功率更高且用药更少。
  • 两种微创青光眼手术装置安全性相似。

研究设计与样本

  • 前瞻性、多中心、随机临床试验。
  • 纳入152例患者152眼,年龄45至84岁,开角型青光眼,Shaffer房角III-IV级,最佳矫正视力20/30或更好,停用所有降眼压药后眼压23至39 mmHg。
  • 排除继发性青光眼(假性剥脱性或色素性青光眼除外)、房角关闭、既往青光眼切开手术或除青光眼外其他显著眼部病变的眼。
  • 研究眼按1:1随机接受1枚Hydrus Microstent或2枚iStent Trabecular Micro Bypass装置单独微创青光眼手术。
  • 术后1天、1周、1、3、6、12个月随访。

主要发现

  • 12个月随访在152例随机受试者中完成148例(97.3%)。
  • 12个月时Hydrus组完全手术成功率更高(P < 0.001)。
  • 12个月时Hydrus组用药数较2-iStent组少0.6种(P = 0.004)。
  • 12个月时Hydrus组无用药比例较2-iStent组高22.6%(P = 0.0057)。
  • 2-iStent组2眼(3.9%)行再次青光眼手术,Hydrus组无;Hydrus组2眼和2-iStent组1眼最佳矫正视力下降≥2行。

关键数值与推荐

  • 完全手术成功定义为无再次青光眼手术、眼压18 mmHg或以下且无青光眼用药。
  • 12个月时Hydrus组完全手术成功率高于2-iStent组(P < 0.001)。
  • 12个月时Hydrus组用药数较2-iStent组少0.6种(P = 0.004)。
  • 12个月时Hydrus组无用药比例较2-iStent组高22.6%(P = 0.0057)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the efficacy of different microinvasive glaucoma surgery (MIGS) devices for reducing intraocular pressure (IOP) and medications in open-angle glaucoma (OAG). DESIGN: Prospective, multicenter, randomized clinical trial. PARTICIPANTS: One hundred fifty-two eyes from 152 patients aged 45 to 84 years with OAG, Shaffer angle grade III-IV, best-corrected visual acuity (BCVA) 20/30 or better, and IOP 23 to 39 mmHg after washout of all hypotensive medications. Eyes with secondary glaucoma other than pseudoexfoliative or pigmentary glaucoma, angle closure, previous incisional glaucoma surgery, or any significant ocular pathology other than glaucoma were excluded. INTERVENTION: Study eyes were randomized 1:1 to standalone MIGS consisting of either 1 Hydrus Microstent (Ivantis, Inc, Irvine, CA) or 2 iStent Trabecular Micro Bypass devices (Glaukos Inc, San Clemente, CA). Follow-up was performed 1 day, 1 week, and 1, 3, 6, and 12 months postoperatively. MAIN OUTCOME MEASURES: Within-group and between-group differences in IOP and medications at 12 months and complete surgical success defined as freedom from repeat glaucoma surgery, IOP 18 mmHg or less, and no glaucoma medications. Safety measures included the frequency of surgical complications, changes in visual acuity, slit-lamp findings, and adverse events. RESULTS: Study groups were well matched for baseline demographics, glaucoma status, medication use, and baseline IOP. Twelve-month follow-up was completed in 148 of 152 randomized subjects (97.3%). At 12 months, the Hydrus had a greater rate of complete surgical success (P < 0.001) and reduced medication use (difference = -0.6 medications, P = 0.004). More Hydrus subjects were medication free at 12 months (difference = 22.6% P = 0.0057). Secondary glaucoma surgery was performed in 2 eyes in the 2-iStent group (3.9%) and in none of the Hydrus eyes. Two eyes in the Hydrus group and 1 in the 2-iStent group had BCVA loss of ≥2 lines. CONCLUSION: Standalone MIGS in OAG with the Hydrus resulted in a higher surgical success rate and fewer medications compared with the 2-iStent procedure. The 2 MIGS devices have similar safety profiles.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Ahmed IIK, Fea A, Au L, et al. A Prospective Randomized Trial Comparing Hydrus and iStent Microinvasive Glaucoma Surgery Implants for Standalone Treatment of Open-Angle Glaucoma: The COMPARE Study. Ophthalmology. 2019. PMID: 31034856. doi:10.1016/j.ophtha.2019.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。